产品名称 | NebuSelect™ Recombinant Biotinylated Human CLEC2D, Avi-hFc-tag |
---|---|
目录号 | NBL-240740 |
别名 | CLEC2D; LLT-1; CLAX; LLT1; OCIL; CLEC2D; CLAXLLT-1; OCILmember D |
外观 | see COA |
分子量 | Arg60-Val191 |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | Q9UHP7-1 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-240740-100ug | 100ug | Inquire | Inquire | |
NBL-240740-1mg | 1mg | Inquire | Inquire | |
NBL-240740-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Biotinylated Human CLEC2D, Avi-hFc-tag
Catalog#:
NBL-240740
Description:
NebuSelect™ Recombinant Biotinylated Human CLEC2D, Avi-hFc-tag(Cat#NBL-240740) is expressed in HEK293 with hFc tag and Avi tag at the N-Terminus.It contains Arg60-Val191.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 59.1 kDa. Due to glycosylation, the protein migrates to 68-75 kDa based on Bis-Tris PAGE result.
Target Name:
CLEC2D; LLT-1; CLAX; LLT1; OCIL; CLEC2D; CLAXLLT-1; OCILmember D
Target Information:
C-type lectin domain family 2, member D (CLEC2D) is implicated in the immune response. Pre-eclampsia and HIV infection have opposing immune responses. The contrasting expression of CLEC2D in HIV infection and pre-eclampsia is demonstrative of the immunosuppressive and pro-inflammatory roles of the respective pathologies.
Amino Acid Sequence:
Arg60-Val191
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.